@article{MAKHILLRJP202014312517,
title = {Effects of Digesti’Vas, Apolyherbal Formulation on Gastrointestinal-Related Measurements
in Rodent Models},
journal = {Research Journal of Pharmacology},
volume = {14},
number = {3},
pages = {33-37},
year = {2020},
issn = {1815-9362},
doi = {rjpharm.2020.33.37},
url = {https://makhillpublications.co/view-article.php?issn=1815-9362&doi=rjpharm.2020.33.37},
author = {K.P.,S. Ume,Abhishek,K.,J.,Shanaz,Nataraj,K.S. and},
keywords = {gastrointestinal motility,Digesti’Vas,Appetite,loperamide,SGOT},
abstract = {The present study evaluated the activity of
Digesti’Vas on gastrointestinal motility, appetite and
hepatoprotective effects in a rodent model. Digesti’Vas is
a polyherbal formulation developed by Suguna Foods Pvt
Ltd. Acute toxicity and gastrointestinal motility activity
were evaluated in mice. Appetite activity and potential
hepatoprotective effects were evaluated in rats. Since,
Digesti’Vas did not exhibit acute toxicity when given
orally up to a concentration of 2000 mg kg–1 bw,
200 m kg–1 body wt. (1/10th of 2000 mg kg–1) was
selected as the median dose. Digesti’Vas showed a
significant increase in mean defecation period
(346.2±65.83 min), comparable to the positive control,
loperamide (383.0±37.83 min) in comparison to the
normal control group (251.2±60.32 min). Digesti’Vas
treatment also led to a significant increase in the
percentage change in body weight (8.367±3.021 g) when
compared to the normal control group (3.618±2.088 g)
and a significant increase in percentage change in food
intake (13.28±3.673 g) when compared to the normal
control group (8.657±2.160 g). When measurements were
done on various liver parameters, it was found that
Digesti’Vas treated animals showed a significant decrease
in serum ALP levels (401.8±10.04 U L–1) compared to
CCl4 treated animals (493.2±108.4 U L–1); comparable to
the positive control, Silymarin (370.5±37.82 U L–1).
Digesti’vas significantly decreased serum SGPT levels
(57.03±66.01 U L–1), compared to CCl4 treated animals
(420.8±214.1 U L–1); in agreement with levels seen in
Silymarin treated animals (61.39±37.87 U L–1).
Furthermore, Digesti’Vas significantly decreased
SGOT (6.953±3.712 U L–1) levels compared to the CCl4
treated group (29.65±5.765 U L–1), in keeping with levels
seen after treatment with Silymarin (10.71±6.135 U L–1).
This study suggests that Digesti’Vas, a herbal preparation
that is formulated by Suguna Foods Pvt Ltd., possesses
antimotility, hepatoprotective and increased appetite
effects in a rodent model. Future studies investing the role
of Digesti’Vas in alleviating gastrointestinal disorders are
certainly warranted.}
}